THOUSAND OAKS, Calif.,
July 29, 2021 /PRNewswire/ -- Amgen
(NASDAQ: AMGN) today announced the appointment of S. Omar Ishrak to
its Board of Directors, effective immediately. Dr.
Ishrak will also serve as a member of the Board's Corporate
Responsibility and Compliance Committee and its Compensation and
Management Development Committee, effective July 30, 2021. Following the appointment of
Dr. Ishrak, the Board will be composed of 12 directors, 11 of whom
are independent.
"Omar is an accomplished business leader with deep experience in
a fast-paced, technology-driven sector of the healthcare industry,"
said Robert A. Bradway, chairman and
chief executive officer of Amgen. "I'm confident he will add
great value to Amgen as we look to harness advances in science and
technology and accelerate our pace of innovation to reach more
patients."
Dr. Ishrak served as chairman and chief executive officer of
Medtronic plc, a global medical technology company, from 2011 to
2020. During his tenure, Medtronic launched numerous innovative
products, expanded geographically, completed several strategic
acquisitions, and strengthened its commitment to social
responsibility. Prior to joining Medtronic, Dr. Ishrak
held numerous leadership positions at GE Healthcare, serving as
president and chief executive officer of GE Healthcare Systems, GE
Healthcare Clinical Systems, and GE Healthcare Ultrasound in his
more than 15 years with the company.
Dr. Ishrak has been a director of Intel Corporation since 2017
and was named chairman of the board in January 2020. Dr. Ishrak has served as
chairman of the board of Compute Health Acquisition Corporation, a
special purpose acquisition company, since January 2021.
Dr. Ishrak also serves on the Board of Directors of the
Cleveland Clinic and is a member of the Board of Trustees of the
Asia Society, an educational organization dedicated to promoting
mutual understanding and strong partnerships between Asia and the U.S. Since May 2021, Dr. Ishrak has been a senior advisor to
Blackstone Life Sciences, a segment of the Blackstone Group Inc.
that invests in the biopharmaceutical and medical technology
industries to advance new treatments for patients.
Dr. Ishrak was born in Bangladesh and received his undergraduate
degree and doctorate from the University of London, King's College. He was inducted
into the American Institute for Medical and Biological Engineering
College of Fellows in 2016, elected as a Fellow of King's College
London in 2017, inducted into the Bakken Society in 2020, and
elected to the National Academy of Engineering in 2020.
About Amgen
Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses
by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the world's leading
independent biotechnology companies, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
CONTACT: Amgen, Thousand Oaks
Megan Fox, 805-447-1423
(media)
Trish Rowland, 805-447-5631
(media)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amgen-appoints-s-omar-ishrak-to-board-of-directors-301344819.html
SOURCE Amgen